Altria's Q2 and H1 results showed flat revenue growth and ongoing challenges in expanding into e-vapor and oral tobacco markets. Despite these setbacks, the company maintains strong cash flow and pricing power, supporting a fair value estimate of $76 per share, implying a 12% potential gain. The current recommendation is to hold shares while awaiting clearer growth signals from new product segments before increasing investment positions.
Steven Fiorillo's Dividend Harvesting Portfolio has grown to $40,536, delivering a 7.87% yield and generating $7,293 in income since inception, with a 43.25% return on investment. Market optimism driven by big tech earnings and AI advancements encour...
Altria Group is set to announce its 56th consecutive annual dividend increase in August, with a predicted rise of 3.7% to 4.7%, bringing dividends to $4.40–$4.44 per share. Despite ongoing declines in cigarette sales, Altria is transforming its busin...
Levi & Korsinsky is investigating whether Altria Group misrepresented the FDA regulatory status of its on! PLUS nicotine pouch and the timing of FDA approvals for other applications. This follows a stock drop after Altria's Q2 2026 results and prior ...
